Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Jounce Therapeutics stock

Own Jounce Therapeutics stock in just a few minutes.

Jounce Therapeutics, Inc is a biotechnology business based in the US. Jounce Therapeutics shares (JNCE) are listed on the NASDAQ and all prices are listed in US Dollars. Jounce Therapeutics employs 128 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Jounce Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – JNCE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Jounce Therapeutics share price

Use our graph to track the performance of JNCE stocks over time.

Jounce Therapeutics shares at a glance

Information last updated 2021-04-30.
52-week range$4.30 - $14.84
50-day moving average $10.27
200-day moving average $9.37
Wall St. target price$16.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $0.63

Buy Jounce Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Jounce Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Jounce Therapeutics under- or over-valued?

Valuing Jounce Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Jounce Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Jounce Therapeutics's EBITDA

Jounce Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $22.6 million.

The EBITDA is a measure of a Jounce Therapeutics's overall financial performance and is widely used to measure a its profitability.

Jounce Therapeutics financials

Revenue TTM $62.3 million
Gross profit TTM $25.3 million
Return on assets TTM -12.53%
Return on equity TTM -22.72%
Profit margin -70.33%
Book value $5.06
Market capitalisation $483.4 million

TTM: trailing 12 months

Shorting Jounce Therapeutics shares

There are currently 1.8 million Jounce Therapeutics shares held short by investors – that's known as Jounce Therapeutics's "short interest". This figure is 42.8% up from 1.2 million last month.

There are a few different ways that this level of interest in shorting Jounce Therapeutics shares can be evaluated.

Jounce Therapeutics's "short interest ratio" (SIR)

Jounce Therapeutics's "short interest ratio" (SIR) is the quantity of Jounce Therapeutics shares currently shorted divided by the average quantity of Jounce Therapeutics shares traded daily (recently around 399583.74717833). Jounce Therapeutics's SIR currently stands at 4.43. In other words for every 100,000 Jounce Therapeutics shares traded daily on the market, roughly 4430 shares are currently held short.

However Jounce Therapeutics's short interest can also be evaluated against the total number of Jounce Therapeutics shares, or, against the total number of tradable Jounce Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Jounce Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Jounce Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0518% of the tradable shares (for every 100,000 tradable Jounce Therapeutics shares, roughly 52 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Jounce Therapeutics.

Find out more about how you can short Jounce Therapeutics stock.

Jounce Therapeutics share dividends

We're not expecting Jounce Therapeutics to pay a dividend over the next 12 months.

Jounce Therapeutics share price volatility

Over the last 12 months, Jounce Therapeutics's shares have ranged in value from as little as $4.3 up to $14.84. A popular way to gauge a stock's volatility is its "beta".

JNCE.US volatility(beta: 1.16)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jounce Therapeutics's is 1.1631. This would suggest that Jounce Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Jounce Therapeutics overview

Jounce Therapeutics, Inc. , a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site